Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 951 to 1000 of 4091 results for patient

  1. Percutaneous laser atherectomy as an adjunct to balloon angioplasty (with or without stenting) for peripheral arterial disease (HTG294)

    Evidence-based recommendations on percutaneous laser atherectomy as an adjunct to balloon angioplasty (with or without stenting) for peripheral arterial disease. This involves using a baloon to widen the artery at the site of the blockage.

  2. Inducing and maintaining normothermia using temperature modulation devices to improve outcomes after stroke or subarachnoid haemorrhage (HTG587)

    Evidence-based recommendations on inducing and maintaining normothermia using temperature modulation devices after stroke or subarachnoid haemorrhage in adults. This involves cooling the body using pads placed on the skin or tubes put into the body.

  3. Atrial fibrillation: DOACs and Vitamin K antagonists (IND247)

    This indicator covers the percentage of patients with atrial fibrillation and a last recorded CHA2DS2-VASc score of 2 or more who are currently prescribed a direct-acting oral anticoagulant (DOAC) if eligible, or a vitamin K antagonist if not eligible for a DOAC or a DOAC is declined, clinically unsuitable or not indicated. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM231

  4. Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy (TA788)

    Evidence-based recommendations on avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy in adults.

  5. Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence (TA810)

    Evidence-based recommendations on abemaciclib (Verzenios) with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence in adults.

  6. Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)

    Evidence-based recommendations on roxadustat (Evrenzo) for treating symptomatic anaemia associated with chronic kidney disease in adults.

  7. Vismodegib for treating basal cell carcinoma (TA489)

    Evidence-based recommendations on vismodegib (Erivedge) for treating basal cell carcinoma in adults.

  8. Upadacitinib for treating active ankylosing spondylitis (TA829)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults.

  9. Insertion of customised exposed titanium implants, without soft tissue cover, for complex orofacial reconstruction (HTG313)

    Evidence-based recommendations on insertion of customised exposed titanium implants, without soft tissue cover, for complex orofacial reconstruction. This involves making the titanium implants specially to fit the person using a model of their face.

  10. NICE real-world evidence framework (ECD9)

    This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence

  11. Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (HTG315)

    Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery.

  12. Stent insertion for bleeding oesophageal varices (HTG261)

    Evidence-based recommendations on stent insertion for bleeding oesophageal varices. This involves temporarily inserting a tube-shaped mesh covered in plastic (called a stent) into the oesophagus.

  13. Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)

    Evidence-based recommendations on ravulizumab (Ultomiris) for treating atypical haemolytic uraemic syndrome in people weighing 10 kg or more.

  14. Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA327)

    Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treating and preventing deep vein thrombosis and pulmonary embolism in adults.

  15. Total distal radioulnar joint replacement for symptomatic joint instability or arthritis (HTG451)

    Evidence-based recommendations on total distal radioulnar joint replacement for symptomatic joint instability or arthritis in adults. This involves removing the wrist end of the ulna and replacing it with a metal prosthesis that also attaches to the wrist end of the radius.

  16. Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer (TA411)

    Evidence-based recommendations on necitumumab (Portrazza) for treating locally advanced or metastatic epidermal growth factor receptor (EGFR)-expressing squamous non-small-cell lung cancer in adults who have not had chemotherapy.

  17. Intranasal phototherapy for allergic rhinitis (HTG473)

    Evidence-based recommendations on intranasal phototherapy for allergic rhinitis in adults. This involves using light to reduce inflammation inside the nose.

  18. Direct C1 lateral mass screw for cervical spine stabilisation (HTG92)

    Evidence-based recommendations on direct C1 lateral mass screw for cervical spine stabilisation. This involves using screws to fix the bones together to treat atlantoaxial fusion in the neck.

  19. Arthroscopic femoro–acetabular surgery for hip impingement syndrome (HTG273)

    Evidence-based recommendations on arthroscopic femoro-acetabular surgery for hip impingement syndrome. This involves removing some of the cartilage or bone, with the aim of reshaping the joint surface.

  20. Endoscopic submucosal dissection of gastric lesions (HTG233)

    Evidence-based recommendations on endoscopic submucosal dissection (ESD) of gastric lesions. This involves inserting a thin telescope through the mouth into the stomach to view the area and removing the lesion with special equipment.

  21. Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)

    Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of invasive urothelial cancer at high risk of recurrence.

  22. Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer (TA737)

    Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer in adults.

  23. Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (TA638)

    Evidence-based recommendations on atezolizumab (Tecentriq) for untreated extensive-stage small-cell lung cancer in adults.

  24. What NICE does

    We're at the forefront of bringing better care to people. We help practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.

  25. Subfascial endoscopic perforator vein surgery (HTG32)

    Evidence-based recommendations on subfascial endoscopic perforator vein surgery. This involves cutting and closing off, or heating and sealing, perforator veins so that blood can no longer go through them.

  26. Endoscopic thoracic sympathectomy for primary facial blushing (HTG331)

    Evidence-based recommendations on endoscopic thoracic sympathectomy for primary facial blushing. This involves cutting off nerve signals to stop the blushing.

  27. GaitSmart rehabilitation exercise programme for gait and mobility issues (HTG716)

    Evidence-based recommendations on GaitSmart rehabilitation exercise programme for gait and mobility issues in adults.

  28. Catheterless oesophageal pH monitoring (HTG121)

    Evidence-based recommendations on catheterless oesophageal pH monitoring. This involves placing a small wireless capsule in the gullet to check the level of acid.

  29. Transvaginal mesh repair of anterior or posterior vaginal wall prolapse (HTG456)

    Evidence-based recommendations on transvaginal mesh repair of anterior or posterior vaginal wall prolapse. This involves inserting a mesh to replace tissue that has weakened and caused the pelvic organs to drop down (prolapse) into the vagina.

  30. Subthalamotomy for Parkinson's disease (HTG38)

    Evidence-based recommendations on subthalamotomy for Parkinson's disease. This involves putting very thin needles into the brain through small holes made in the skull.

  31. Managed access

    Managed access allows people to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.

  32. Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer (HTG522)

    Evidence-based recommendations on transurethral laser ablation for recurrent non-muscle-invasive bladder cancer in adults. This involves using a laser inserted into the bladder to destroy the cancer cells.

  33. Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)

    Evidence-based recommendations on lanadelumab (Takhzyro) for preventing recurrent attacks of hereditary angioedema in people aged 12 and over.

  34. Urinary tract infection in children and young people (QS36)

    This quality standard covers diagnosing and managing urinary tract infection in infants, children and young people (under 16). It includes new and recurrent infections of the upper or lower urinary tract. It describes high-quality care in priority areas for improvement.

  35. Retrobulbar irradiation for thyroid eye disease (HTG94)

    Evidence-based recommendations on retrobulbar irradiation for thyroid eye disease. This involves using radiation to target the tissue behind the eyeball and reduce inflammation.

  36. Epiretinal brachytherapy for wet age-related macular degeneration (HTG279)

    Evidence-based recommendations on epiretinal brachytherapy for wet age related macular degeneration. This involves using radiation therapy used to destroy the new blood vessels.

  37. Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer (HTG659)

    Evidence-based recommendations on biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer. This involves pushing the rectum slightly away from the prostate by inserting a balloon or injecting a gel (spacer) between them.

  38. Canagliflozin in combination therapy for treating type 2 diabetes (TA315)

    Evidence-based recommendations on canagliflozin (Invokana) in combination therapy for treating type 2 diabetes in adults.

  39. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension (HTG410)

    Evidence-based recommendations on balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension in adults. This involves inserting and inflating a balloon in blocked blood vessels in the lungs to improve blood flow.

  40. Endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limb (HTG339)

    Evidence-based recommendations on endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limb. This involves dividing appropriate parts of the sympathetic chain beside the vertebral column to reduce sweating.

  41. Tezepelumab for treating severe asthma (TA880)

    Evidence-based recommendations on tezepelumab (Tezspire) for treating severe asthma in people 12 years and over.

  42. Tinnitus: assessment and management (NG155)

    This guideline covers the assessment, investigation and management of tinnitus in primary, community and secondary care. It offers advice to healthcare professionals on supporting people presenting with tinnitus and on when to refer for specialist assessment and management.

  43. Inditherm patient warming mattress for the prevention of inadvertent hypothermia (MTG7)

    In March 2018, NICE reviewed this guidance and recommended it should be withdrawn as it has been updated and replaced by the NICE guideline on hypothermia: prevention and management in adults having surgery. For a copy of the review decision please contact nice@nice.org.uk.

  44. Percutaneous mechanical thrombectomy for acute deep vein thrombosis of the leg (HTG516)

    Evidence-based recommendations on percutaneous mechanical thrombectomy for acute deep vein thrombosis of the leg in adults. This involves removing the clot through a catheter inserted into the vein.

  45. Haemorrhoidal artery ligation (HTG218)

    Evidence-based recommendations on haemorrhoidal artery ligation. This involves tying the blood vessels and folding up the inside lining of the bowel to reduce blood supply to the haemorrhoids and make them shrink.

  46. Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma (TA677)

    Evidence-based recommendations on brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma in adults who have previously had a Bruton’s tyrosine kinase (BTK) inhibitor.

  47. Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (TA865)

    Evidence-based recommendations on nivolumab (Opdivo) with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma in adults.